scispace - formally typeset
M

Masatoshi Tateno

Researcher at University of California, San Francisco

Publications -  22
Citations -  3366

Masatoshi Tateno is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Virus & Antibody. The author has an hindex of 12, co-authored 21 publications receiving 3314 citations. Previous affiliations of Masatoshi Tateno include Juntendo University.

Papers
More filters
Journal ArticleDOI

Vascular Endothelial Growth Factor and Angiopoietin-1 Stimulate Postnatal Hematopoiesis by Recruitment of Vasculogenic and Hematopoietic Stem Cells

TL;DR: In this paper, VEGF and angiopoietin-1 (Ang-1) levels were elevated by injecting recombinant protein or adenoviral vectors expressing soluble VEGFs165, matrix-bound VEGf189, or Ang-1 into mice, which was associated with an induction of hematopoiesis and increased marrow cellularity.
Journal ArticleDOI

Biologic features of HIV-1 that correlate with virulence in the host

TL;DR: The development of disease was found to be correlated with the emergence of HIV-1 variants that were more cytopathic in vitro as the disease progressed and that replicated more efficiently in a wide variety of different human cells.
Journal ArticleDOI

Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells.

TL;DR: It is demonstrated that overexpression of SDF1 in the peripheral circulation results in the mobilization of hematopoietic cells with repopulating capacity, progenitor cells, and precursor cells.
Journal ArticleDOI

The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells.

TL;DR: The results indicate that the FcRIII receptor on human macrophages and possibly another Fc receptors on human CD4+ lymphocytes mediate antibody-dependent enhancement of HIV infectivity and that this phenomenon proceeds through a mechanism independent of the CD4 protein.
Journal ArticleDOI

Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias

TL;DR: Effective antiangiogenic therapies to treat VEGF-producing, VEGFR-expressing leukemias may require blocking both paracrine and autocrine VEGf/VEGFR-2 angiogenic loops to achieve remission and long-term cure.